October 4, 2023

Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid Taper

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Sarilumab showed significant efficacy in achieving sustained remission and reducing the cumulative glucocorticoid dose in patients with a relapse of polymyalgia rheumatica during glucocorticoid tapering. (Funded by Sanofi and Regeneron Pharmaceuticals; SAPHYR ClinicalTrials.gov number, NCT03600818.).

Me gusta

Guardar

Cite This Study

Spiera et al. (Wed,) studied this question.

synapsesocial.com/papers/69daa3232d871caad68358b8 https://doi.org/https://doi.org/10.1056/nejmoa2303452

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Clinical outcomes, quality of life, and diagnostic uncertainty in the first year of polymyalgia rheumatica2007 · 146 citations
2Prednisone plus Methotrexate for Polymyalgia Rheumatica2004 · 256 citations
3The Epidemiology of Corticosteroid-Induced Osteoporosis: a Meta-analysis2002 · 1,290 citations
4Long-term safety of sarilumab in rheumatoid arthritis: an integrated analysis with up to 7 years’ follow-up2019 · 69 citations
5The glucocorticoid toxicity index: Measuring change in glucocorticoid toxicity over time2022 · 92 citations

Me gusta

Guardar